Meis Paul J, Klebanoff Mark, Thom Elizabeth, Dombrowski Mitchell P, Sibai Baha, Moawad Atef H, Spong Catherine Y, Hauth John C, Miodovnik Menachem, Varner Michael W, Leveno Kenneth J, Caritis Steve N, Iams Jay D, Wapner Ronald J, Conway Deborah, O'Sullivan Mary J, Carpenter Marshall, Mercer Brian, Ramin Susan M, Thorp John M, Peaceman Alan M, Gabbe Steven
Department of Obstetrics and Gynecology, Wake Forest University, Winston-Salem, NC 27157, USA.
N Engl J Med. 2003 Jun 12;348(24):2379-85. doi: 10.1056/NEJMoa035140.
Women who have had a spontaneous preterm delivery are at greatly increased risk for preterm delivery in subsequent pregnancies. The results of several small trials have suggested that 17 alpha-hydroxyprogesterone caproate (17P) may reduce the risk of preterm delivery.
We conducted a double-blind, placebo-controlled trial involving pregnant women with a documented history of spontaneous preterm delivery. Women were enrolled at 19 clinical centers at 16 to 20 weeks of gestation and randomly assigned by a central data center, in a 2:1 ratio, to receive either weekly injections of 250 mg of 17P or weekly injections of an inert oil placebo; injections were continued until delivery or to 36 weeks of gestation. The primary outcome was preterm delivery before 37 weeks of gestation. Analysis was performed according to the intention-to-treat principle.
Base-line characteristics of the 310 women in the progesterone group and the 153 women in the placebo group were similar. Treatment with 17P significantly reduced the risk of delivery at less than 37 weeks of gestation (incidence, 36.3 percent in the progesterone group vs. 54.9 percent in the placebo group; relative risk, 0.66 [95 percent confidence interval, 0.54 to 0.81]), delivery at less than 35 weeks of gestation (incidence, 20.6 percent vs. 30.7 percent; relative risk, 0.67 [95 percent confidence interval, 0.48 to 0.93]), and delivery at less than 32 weeks of gestation (11.4 percent vs. 19.6 percent; relative risk, 0.58 [95 percent confidence interval, 0.37 to 0.91]). Infants of women treated with 17P had significantly lower rates of necrotizing enterocolitis, intraventricular hemorrhage, and need for supplemental oxygen.
Weekly injections of 17P resulted in a substantial reduction in the rate of recurrent preterm delivery among women who were at particularly high risk for preterm delivery and reduced the likelihood of several complications in their infants.
有过自然早产史的女性在后续妊娠中早产风险大幅增加。几项小型试验的结果表明,己酸17α-羟孕酮(17P)可能降低早产风险。
我们进行了一项双盲、安慰剂对照试验,纳入有自然早产记录史的孕妇。孕妇在妊娠16至20周时在19个临床中心入组,并由中央数据中心按2:1的比例随机分配,分别接受每周一次250毫克17P注射或每周一次惰性油安慰剂注射;注射持续至分娩或妊娠36周。主要结局是妊娠37周前早产。分析按照意向性分析原则进行。
孕酮组的310名女性和安慰剂组的153名女性的基线特征相似。17P治疗显著降低了妊娠37周前分娩的风险(发生率,孕酮组为36.3%,安慰剂组为54.9%;相对风险,0.66[95%置信区间,0.54至0.81])、妊娠35周前分娩的风险(发生率,20.6%对30.7%;相对风险,0.67[95%置信区间,0.48至0.93])以及妊娠32周前分娩的风险(11.4%对19.6%;相对风险,0.58[95%置信区间,0.37至0.91])。接受17P治疗的女性的婴儿坏死性小肠结肠炎、脑室内出血和需要补充氧气的发生率显著较低。
每周注射17P可使早产风险特别高的女性复发性早产率大幅降低,并降低其婴儿发生几种并发症的可能性。